News
The Evolving IPF Landscape
What Nerandomilast Means for Future Antifibrotic Development In recent blogs we have reflected on the promise shown by the orally-delivered preferential PDE4B inhibitor, nerandomilast, now
Inhaled Therapies for IPF – an update
In a recent blog we reflected on key presentations at the ERS relating to pulmonary fibrosis, including the promise shown by the orally-delivered preferential PDE4B
Reflections from ERS 2025
From a Pulmonary fibrosis perspective, the ERS meeting in Amsterdam (27 September to 1 October, 2025) provided a combination of hope, challenge and satisfaction for
Society for Medicines Research (SMR) Meeting on Women’s Health
Darcey Black, Translational Science Director at TherapeutAix, will be attending and co-chairing a session at the forthcoming SMR Meeting on Women’s Health, taking place at
Biking for Action Medical Research
Our co-founder and Director of Translational, Darcey Black, is planning to take part in the BiotechBikers “Catalyst” Charity Event, a 250-mile cycle ride from London
TherapeutAix Roundup: 2024
As another year comes to a close, we reflect on 12 months filled with innovation and collaboration at TherapeutAix. From kickstarting the year with strategic
Exploring the Potential of Inhalation Therapies for IPF: Lessons from Asthma
A few weeks ago, our updated review on the state of drug development in Idiopathic Pulmonary Fibrosis (IPF) was published in Drug Discovery Today. This update